MDGL Jan 2025 410.000 call
- Investor's Business Daily
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
Madrigal Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
- GlobeNewswire
Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress
Late-breaking AI-based analysis of MAESTRO-NASH biopsy data demonstrates Rezdiffra improved key fibrotic features that are predictive of progression to decompensated cirrhosisNoninvasive test data through three years of treatment demonstrate durable treatment response to Rezdiffra; 91% of patients achieved improvement or stabilization of liver stiffness First analysis of health-related quality of life data from MAESTRO-NASH demonstrates Rezdiffra improved patient worry, health distress and stigm
- Investor's Business Daily
Madrigal, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
Madrigal stock plummeted Wednesday on detailed results from a study of Eli Lilly's weight-loss drug in patients with a serious liver disease.
